Showing results (1-10 of 31) with videos related to
Sort By:
Pageof 4
Methods in Molecular Biology (Clifton, N.J.)|June 18, 2004
The CGG repeat and the FMR1 geneVioleta Stoyanova, Ben A OostraEuropean Journal of Ophthalmology|March 19, 2024
Inherited retinal dystrophies and orphan designations in the European UnionJane Moseley, Tim Leest, Kristina Larsson, et al.FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|September 21, 2004
Loss of FMR1 hypermethylation in somatic cell heterokaryonsVioleta Stoyanova, Stefano Rossetti, Leontine VAN Unen, et al.Frontiers in Medicine|July 12, 2021
Regulatory Standards in Orphan Medicinal Product Designation in the EUStelios Tsigkos, Segundo Mariz, Maria Elzbieta Sheean, et al.British Journal of Clinical Pharmacology|March 27, 2021
Haemophilia, state of the art and new therapeutic opportunities, a regulatory perspectiveFrancesca Tomeo, Segundo Mariz, Angelo Loris Brunetta, et al.European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|November 19, 2010
Insomnia medication: do published studies reflect the complete picture of efficacy and safety?Taina Mattila, Violeta Stoyanova, André Elferink, et al.European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|June 19, 2012
The placebo arm in clinical studies for treatment of psychiatric disorders: a regulatory dilemmaChristine Gispen-de Wied, Violeta Stoyanova, Yang Yu, et al.Frontiers in Medicine|June 1, 2017
Advanced Therapy Medicinal Products for Rare Diseases: State of Play of Incentives Supporting Development in EuropeAndreas M Farkas, Segundo Mariz, Violeta Stoyanova-Beninska, et al.Journal of Clinical Pharmacology|September 8, 2018
Dose-Finding Studies Among Orphan Drugs Approved in the EU: A Retrospective AnalysisYvonne Schuller, Christine Gispen-de Wied, Carla E M Hollak, et al.Oncogene|September 21, 2002
The transcriptional corepressor MTG16a contains a novel nucleolar targeting sequence deranged in t (16; 21)-positive myeloid malignanciesAndré T Hoogeveen, Stefano Rossetti, Violeta Stoyanova, et al.Pageof 4